哈哈哈哈，被告了。_老虎社区_美港股上老虎

海盗辛伯达
2020-04-16

哈哈哈哈，被告了。

Notice of Lead Plaintiff Deadline for Shareholders in the Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in

Notice of Lead Plaintiff Deadline for Shareholders in the Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":926313632,"tweetId":"926313632","gmtCreate":1586981306226,"gmtModify":1704362823217,"author":{"id":307892809294465,"authorId":307892809294465,"authorIdStr":"307892809294465","name":"海盗辛伯达","avatar":"https://static.tigerbbs.com/e30d3fe40506ce20872174742229771d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>哈哈哈哈，被告了。</p></body></html>","htmlText":"<html><head></head><body><p>哈哈哈哈，被告了。</p></body></html>","text":"哈哈哈哈，被告了。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/926313632","repostId":2027787996,"repostType":2,"repost":{"id":"2027787996","pubTimestamp":1586955600,"share":"https://www.laohu8.com/m/news/2027787996?lang=&edition=full","pubTime":"2020-04-15 21:00","market":"us","language":"en","title":"Notice of Lead Plaintiff Deadline for Shareholders in the Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2027787996","media":"Business Wire","summary":"Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in ","content":"<html><body><div><p type=\"text\">Robbins Geller Rudman &amp; Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) common stock between February 14, 2020 and March 9, 2020 (the \"Class Period\"). The case is captioned <i>McDermid v. Inovio Pharmaceuticals, Inc.</i>, No. 20-cv-01402, and is assigned to Judge Gerald J. Pappert. The <i>Inovio Pharmaceuticals</i> securities class action lawsuit charges Inovio Pharmaceuticals and its current Chief Executive Officer (\"CEO\") with violations of the Securities Exchange Act of 1934.</p><p type=\"text\">Inovio Pharmaceuticals purports to be a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. In the United States, fears over the novel coronavirus, COVID-19, have had devastating economic and social consequences. Large public gatherings and major events have been canceled. Employees have been told to work from home, universities have moved all classes online, and elementary schools have closed for sanitizing. Currently, there is no vaccine available to prevent the spread of COVID-19.</p><p type=\"text\">During the Class Period, defendants capitalized on widespread COVID-19 fears by falsely claiming that Inovio Pharmaceuticals had developed a vaccine for COVID-19. First, on February 14, 2020, Inovio Pharmaceuticals CEO J. Joseph Kim appeared on <i>Fox Business News</i> and stated that Inovio Pharmaceuticals had developed a COVID-19 vaccine \"in a matter of about three hours once we had the DNA sequence from the virus,\" and that \"our goal is to start phase one human testing in the U.S. early this summer.\" In response, Inovio Pharmaceuticals’ stock price rose more than 10% over the next few trading days, on enormous trading volume.</p><p type=\"text\">Two weeks later, following a well-publicized March 2, 2020 meeting with President Trump to discuss the COVID-19 outbreak, defendant Kim again claimed that Inovio Pharmaceuticals had developed a COVID-19 vaccine, stating that \"we were able to fully construct our vaccine within three hours . . . . Our plan is to start [U.S. based COVID-19 trials] in April of this year.\" The market responded favorably to Kim’s statement and Inovio Pharmaceuticals’ stock price shot up from its closing price of $4.28 per share on February 28, 2020 to close at $14.09 per share on March 6, 2020, and then reach an intra-day high of $19.36 per share on March 9, 2020 before closing at $9.83 per share.</p><p type=\"text\">However, in truth, Inovio Pharmaceuticals had not developed a COVID-19 vaccine. On March 9, 2020, before trading commenced, Citron Research exposed defendants’ misstatements, calling for an SEC investigation into the Company’s \"ludicrous and dangerous claim that they designed a [COVID-19] vaccine in 3 hours.\" In response to the news, Inovio Pharmaceuticals’ stock price plummeted from its March 9, 2020 opening price of $18.72 per share to close at $9.83 per share. The following day, March 10, 2020, Inovio Pharmaceuticals’ stock price fell from its $9.30 per share opening price to close at $5.70 per share. The two-day price drop wiped out approximately $643 million of Inovio Pharmaceuticals’ market capitalization and marked a 70% decline from the stock’s Class Period intra-day high. In a message to shareholders that same day, Inovio Pharmaceuticals attempted to blunt the Citron revelations but only highlighted its own misstatements, admitting that it had not developed a COVID-19 vaccine, but rather, had merely \"designed a vaccine construct\" – <i>i.e</i>., a precursor for a vaccine – and that it believed it had a \"viable approach to address the COVID-19 outbreak.\"</p><p type=\"text\">The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Inovio Pharmaceuticals common stock during the Class Period to seek appointment as lead plaintiff in the <i>Inovio Pharmaceuticals</i> securities class action lawsuit. A lead plaintiff acts on behalf of all other class members in directing the <i>Inovio Pharmaceuticals</i> securities class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the <i>Inovio Pharmaceuticals</i> securities class action lawsuit. An investor’s ability to share in any potential future recovery of the <i>Inovio Pharmaceuticals</i> securities class action lawsuit is not dependent upon serving as lead plaintiff. <b>If you wish to serve as lead plaintiff of the <i>Inovio Pharmaceuticals</i> securities class action lawsuit or have questions concerning your rights regarding the <i>Inovio Pharmaceuticals</i> securities class action lawsuit, please visit our website by clicking here or contact Michael Albert at 800/449-4900 or 619/231-1058, or via e-mail at malbert@rgrdlaw.com.</b> Lead plaintiff motions for the <i>Inovio Pharmaceuticals</i> securities class action lawsuit must be filed with the court no later than May 12, 2020.</p><div><p type=\"text\">Robbins Geller Rudman &amp; Dowd LLP is one of the world’s leading law firms representing investors in securities litigation. With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history. For seven consecutive years, <a href=\"https://laohu8.com/S/ISFFF\">ISS</a> Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements. Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims. Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide. Robbins Geller attorneys are consistently recognized by courts, professional organizations, and the media as leading lawyers in the industry. Please visit http://www.rgrdlaw.com for more information.</p><p type=\"text\"><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20200415005005/en/</span></p><p type=\"text\"><b>Contacts</b></p><p type=\"text\">Robbins Geller Rudman &amp; Dowd LLP<br/>Michael Albert, 800-449-4900<br/>malbert@rgrdlaw.com</p><p type=\"text\">https://www.linkedin.com/company/rgrdlaw <br/>https://twitter.com/rgrdlaw <br/>https://www.facebook.com/rgrdlaw</p></div></div></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Notice of Lead Plaintiff Deadline for Shareholders in the Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNotice of Lead Plaintiff Deadline for Shareholders in the Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-04-15 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/notice-lead-plaintiff-deadline-shareholders-130000925.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ...</p>\n\n<a href=\"https://finance.yahoo.com/news/notice-lead-plaintiff-deadline-shareholders-130000925.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/lo/api/res/1.2/OLJo1p7uh8w26ZqXjWldIA--/YXBwaWQ9eXZpZGVvZmVlZHM7dz0xMjA7aD00OQ--/https://media.zenfs.com/en/business-wire.com/1d9663e998e6d286252dd55d80fa066e","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://finance.yahoo.com/news/notice-lead-plaintiff-deadline-shareholders-130000925.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2027787996","content_text":"Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) common stock between February 14, 2020 and March 9, 2020 (the \"Class Period\"). The case is captioned McDermid v. Inovio Pharmaceuticals, Inc., No. 20-cv-01402, and is assigned to Judge Gerald J. Pappert. The Inovio Pharmaceuticals securities class action lawsuit charges Inovio Pharmaceuticals and its current Chief Executive Officer (\"CEO\") with violations of the Securities Exchange Act of 1934.Inovio Pharmaceuticals purports to be a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. In the United States, fears over the novel coronavirus, COVID-19, have had devastating economic and social consequences. Large public gatherings and major events have been canceled. Employees have been told to work from home, universities have moved all classes online, and elementary schools have closed for sanitizing. Currently, there is no vaccine available to prevent the spread of COVID-19.During the Class Period, defendants capitalized on widespread COVID-19 fears by falsely claiming that Inovio Pharmaceuticals had developed a vaccine for COVID-19. First, on February 14, 2020, Inovio Pharmaceuticals CEO J. Joseph Kim appeared on Fox Business News and stated that Inovio Pharmaceuticals had developed a COVID-19 vaccine \"in a matter of about three hours once we had the DNA sequence from the virus,\" and that \"our goal is to start phase one human testing in the U.S. early this summer.\" In response, Inovio Pharmaceuticals’ stock price rose more than 10% over the next few trading days, on enormous trading volume.Two weeks later, following a well-publicized March 2, 2020 meeting with President Trump to discuss the COVID-19 outbreak, defendant Kim again claimed that Inovio Pharmaceuticals had developed a COVID-19 vaccine, stating that \"we were able to fully construct our vaccine within three hours . . . . Our plan is to start [U.S. based COVID-19 trials] in April of this year.\" The market responded favorably to Kim’s statement and Inovio Pharmaceuticals’ stock price shot up from its closing price of $4.28 per share on February 28, 2020 to close at $14.09 per share on March 6, 2020, and then reach an intra-day high of $19.36 per share on March 9, 2020 before closing at $9.83 per share.However, in truth, Inovio Pharmaceuticals had not developed a COVID-19 vaccine. On March 9, 2020, before trading commenced, Citron Research exposed defendants’ misstatements, calling for an SEC investigation into the Company’s \"ludicrous and dangerous claim that they designed a [COVID-19] vaccine in 3 hours.\" In response to the news, Inovio Pharmaceuticals’ stock price plummeted from its March 9, 2020 opening price of $18.72 per share to close at $9.83 per share. The following day, March 10, 2020, Inovio Pharmaceuticals’ stock price fell from its $9.30 per share opening price to close at $5.70 per share. The two-day price drop wiped out approximately $643 million of Inovio Pharmaceuticals’ market capitalization and marked a 70% decline from the stock’s Class Period intra-day high. In a message to shareholders that same day, Inovio Pharmaceuticals attempted to blunt the Citron revelations but only highlighted its own misstatements, admitting that it had not developed a COVID-19 vaccine, but rather, had merely \"designed a vaccine construct\" – i.e., a precursor for a vaccine – and that it believed it had a \"viable approach to address the COVID-19 outbreak.\"The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Inovio Pharmaceuticals common stock during the Class Period to seek appointment as lead plaintiff in the Inovio Pharmaceuticals securities class action lawsuit. A lead plaintiff acts on behalf of all other class members in directing the Inovio Pharmaceuticals securities class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Inovio Pharmaceuticals securities class action lawsuit. An investor’s ability to share in any potential future recovery of the Inovio Pharmaceuticals securities class action lawsuit is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff of the Inovio Pharmaceuticals securities class action lawsuit or have questions concerning your rights regarding the Inovio Pharmaceuticals securities class action lawsuit, please visit our website by clicking here or contact Michael Albert at 800/449-4900 or 619/231-1058, or via e-mail at malbert@rgrdlaw.com. Lead plaintiff motions for the Inovio Pharmaceuticals securities class action lawsuit must be filed with the court no later than May 12, 2020.Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities litigation. With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history. For seven consecutive years, ISS Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements. Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims. Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide. Robbins Geller attorneys are consistently recognized by courts, professional organizations, and the media as leading lawyers in the industry. Please visit http://www.rgrdlaw.com for more information.View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005005/en/ContactsRobbins Geller Rudman & Dowd LLPMichael Albert, 800-449-4900malbert@rgrdlaw.comhttps://www.linkedin.com/company/rgrdlaw https://twitter.com/rgrdlaw https://www.facebook.com/rgrdlaw","news_type":1},"isVote":1,"tweetType":1,"viewCount":787,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}